Qualthera Health Corporation, dedicated to building a nationwide network of quality, patient-centered compounding pharmacies, has announced the official launch of Qualthera Pharmaceuticals Ltd. Co., a research-driven subsidiary dedicated to drug repurposing and innovative delivery systems. This expansion marks a significant step forward in accelerating pharmaceutical innovation, leveraging real-world patient insights to develop new therapies with streamlined development.

“With Qualthera Pharmaceuticals, we are redefining how underutilized compounds can be developed, repurposed and delivered,” said Donald Prentiss, CEO of Qualthera Health Corporation. “Our work doesn’t start in a lab—it starts with real patients and real prescribing challenges. This ensures every compound we explore is grounded in clinical relevance and tangible patient need.”

Revolutionizing Drug Repurposing

Unlike traditional pharmaceutical R&D, Qualthera Pharmaceuticals focuses on identifying new therapeutic uses for active pharmaceutical ingredients (APIs) that are already approved and off-patent. By repurposing compounds with known pharmacology and safety profiles, the company aims to bring innovative therapies to market more efficiently, taking advantage of existing regulatory pathways and leveraging established safety data.

“In the past, drug repurposing relied heavily on academic research or abandoned R&D programs,” said Prentiss. “At Qualthera Pharmaceuticals, we take a different approach. We analyze real-world prescribing trends, patient access challenges, and therapeutic gaps, then assess compound viability and delivery innovation. It’s repurposing with intent, not just exploration.”

Flagship Product: The Biodegradable CBD Implant

Leading Qualthera Pharmaceuticals’ portfolio is its patent-pending biodegradable CBD implant, designed to provide consistent, long-term therapeutic exposure to cannabidiol (CBD). This innovative technology addresses limitations in traditional CBD formats, including inconsistent absorption, which may lead to unpredictable therapeutic outcomes.

“We’re not just repurposing CBD—we’re re-engineering how it’s delivered,” added Prentiss. “By creating a long-acting implant, we aim to unlock its potential for treating chronic pain and neurodegenerative disorders such as Alzheimer’s and Parkinson’s, where steady exposure is critical, and treatment options remain limited.”

Qualthera Pharmaceuticals intends to pursue FDA approval for its CBD implant, which could become the first implantable formulation of CBD and only the second FDA-approved CBD drug in the U.S. The company is also evaluating three additional drug candidates targeting ALS, weight loss, and opioid use disorder, reinforcing its commitment to tackling high-need, scalable therapeutic opportunities.

A Bold New Chapter for Qualthera

The launch of Qualthera Pharmaceuticals Ltd. Co. represents the next evolution of Qualthera Health Corporation, expanding from personalized compounding into scalable pharmaceutical development.

“Our guiding principle has always been ‘quality therapy for life’—from individual patients to broader populations,” said Prentiss. “This subsidiary allows us to build a pipeline of transformative therapies, all informed by real-world medical challenges and science-driven solutions.”

Source: businesswire.com